Read More

Ambrx Announces ARX517, A PSMA-Targeted ADC, Demonstrates 52% PSA50 (≥50% Reduction) And A Highly Differentiated Safety And PK Profile In Patients With mCRPC, Who Progressed On Multiple FDA-Approved Treatments

Newly published data from the Phase 1 portion of the on-going Phase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at

AMAM